DV
Dividend Vision

LIMN — Liminatus Pharma, Inc. Class A Common Stock

Liminatus Pharma, Inc. Class A Common Stock (LIMN)

Total return is -98.6% over the past 5.2 years, 197.5 points behind SPY at 98.9%. Its deepest 1-year drawdown was 97.8%.

Liminatus Pharma is a pre-clinical stage biopharmaceutical company developing cancer therapies, including IBA101, a humanized anti-CD47 monoclonal antibody currently in Phase I clinical trials for advanced solid cancers such as non-small cell lung cancer. The company does not currently distribute dividends. This security appeals to investors with high risk tolerance seeking exposure to early-stage biopharmaceutical development.

LIMN key facts

Asset type
Stock
Asset class
Equity
Inception date
05/26/2021
Last close
$0.14
Market cap
$7,050,965
Average volume
13216600.0
Beta
0.744
Payout ratio
0.0
Forward P/E
0.0
EPS
$-0.25